Navigation Links
Abbott's Ibis Technology Identified Fatal Disease Organism in Afghanistan
Date:2/7/2011

WASHINGTON, Feb. 7, 2011 /PRNewswire/ -- Today, at the American Society for Microbiology Conference on Biodefense and Emerging Diseases, scientists from Abbott Molecular presented data showing the unique power of the company's Ibis technology to identify and further characterize unknown disease-causing pathogens to help aid in the bioforensic analysis of pandemic outbreaks.  

In a presentation at the conference, Tim Motley, principal scientist, Ibis Biosciences, a subsidiary of Abbott (NYSE: ABT), reported on genotypic characterization of Yersina pestis after a severe outbreak of an unknown disease in Afghanistan's Nimorz Province in December 2007.  Eighty-three people experienced severe fever, vomiting and diarrhea, and 17 died.  All had consumed camel meat.  Due to the gastrointestinal symptoms and disease severity, anthrax was suspected.

Blood from a patient sample and several camel tissue specimens were analyzed using the Ibis T5000 biosensor, a precursor to the PLEX-ID™ system developed and marketed by Abbott.  The analysis showed both the blood and camel tissue specimens tested positive for Yersina pestis, the causative agent for plague.  This was the first reported case of plague in Afghanistan.  Other test methods, including culture, had failed to identify the causative organism.  

"With the PLEX-ID technology, we were able to genetically characterize the strain, identify its unique genetic structure and develop a microbial forensic marker that could be used to identify this strain should future outbreaks occur," said Motley.  He added that the ability of PLEX-ID to combine polymerase chain reaction (PCR) and electrospray ionization mass spectrometry allows laboratories to identify an unknown organism and determine its specific genotype.

Motley explained that the Afghanistan case shows the broad applicability of PLEX-ID technology for use in identifying and characterizing infectious agents before they become widespread.  

About PLEX-ID

Currently intended for non-diagnostic use, PLEX-ID is the only high-throughput technology that offers rapid and broad identification, detailed genotyping and characterization, and recognition of emerging organisms. The system employs a combination of molecular technologies, including polymerase chain reaction (PCR) for gene amplification and mass spectrometry analysis to rapidly characterize known and unknown organisms.  

It is designed to address a significant unmet need by providing test results in less than eight hours instead of three or more days required with current blood and tissue culture-based methods.

PLEX-ID is designed to identify a broad range of bacteria, viruses, fungi, certain parasites, and also provide information about drug resistance, virulence, and strain type.  Anticipated public health and biodefense applications include epidemiologic research and identification of emerging or previously unknown agents.  In addition, the system is being used for forensic characterization of human samples.

In 2009, PLEX-ID was recognized by both The Scientist and the Wall Street Journal as top scientific innovations of the year.  The Scientist honored the system because it can detect and characterize a broad range of microorganisms in any given sample.  The Journal selected PLEX-ID as its Gold winner of the 2009 Wall Street Journal Technology Innovation Awards because it promises to alert health officials to new disease strains, may also guard against bio-terrorism, and enable hospitals to identify antibiotic-resistant bacteria in its environment.

Since its development in 2005, PLEX-ID technology has been deployed in 20 sites around the United States, including the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott information is available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
2. Endologix Announces Favorable Clinical Results for Nellix Technology
3. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
4. US Army Study Shows STB Lifesaving Technologys® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
5. Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List
6. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
7. Crestwood Technology Group Receives Silver Boeing Performance Excellence Award
8. Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase
9. Encinitas Nursing and Rehabilitation Center First in Southern California to Deploy Voice Technology for Outcomes-Based Care
10. Frost & Sullivan Recognizes BeClose as a Technology Innovator for Aging Independently in North America
11. Medizone Internationals Mass-Market Sterilization Technology to be Produced by Canadian Medical Device Heavyweights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):